Soligenix Expands European Advisory Board to Enhance Rare Disease Development Strategy

Soligenix Strengthens Development Strategy with Expanded European Medical Advisory Board

Soligenix, Inc., a late-stage biopharmaceutical firm devoted to developing treatments for rare diseases, takes a significant step forward by expanding its European Medical Advisory Board (MAB). This strategic enhancement aims to bolster the company’s guidance as it seeks marketing approvals for its innovative therapies in Europe. The MAB now includes prominent dermatologists, Drs. Scarisbrick and Vermeer, joining an already esteemed group of experts. This expansion reflects Soligenix's commitment to leveraging top-tier expertise in its ongoing efforts, particularly as it prepares for a pivotal Phase 3 clinical trial of HyBryte™. The trial, designed to evaluate the efficacy of synthetic hypericin for treating early-stage cutaneous T-cell lymphoma (CTCL), is set to enroll approximately 80 participants and is targeted for completion by the latter half of 2026.

The inclusion of renowned specialists in the MAB underscores Soligenix's strategic approach to navigating the complexities of clinical development and regulatory approval processes in the European Union (EU) and the United Kingdom (UK). Christopher J. Schaber, PhD, the company's President and CEO, highlights the essential role played by the advisory board in shaping clinical strategies and addressing health economics and reimbursement issues. The expert feedback offered by the MAB is crucial for ensuring that HyBryte™ not only meets clinical endpoints but also aligns with patient needs, thereby facilitating a smoother path toward commercialization.

With the expanded MAB in place, Soligenix aims to effectively manage regulatory interactions and enhance the overall quality of its clinical studies. This proactive measure is crucial as the company prepares for potential future milestones and seeks to address unmet medical needs in the rare disease space. The integration of expert insights into its clinical development strategy positions Soligenix favorably in the competitive biopharmaceutical landscape.

In conjunction with this strategic advisory board expansion, Soligenix has also successfully completed a public offering, raising approximately $7.5 million in gross proceeds. The funds generated will play a vital role in supporting research and development, commercialization activities, and general corporate purposes, extending the company's cash runway through the end of 2026.

This dual approach of securing expert guidance while enhancing financial stability positions Soligenix to advance its promising therapies and continue its mission of addressing the challenges faced by patients with rare diseases effectively.